首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Novel Cycloheximide Derivatives Targeting the Moonlighting Protein Mip Exhibit Specific Antimicrobial Activity Against Legionella pneumophila
【24h】

Novel Cycloheximide Derivatives Targeting the Moonlighting Protein Mip Exhibit Specific Antimicrobial Activity Against Legionella pneumophila

机译:靶向月光照蛋白Mip的新型环己酰亚胺衍生物对嗜肺军团菌具有特定的抗菌活性

获取原文
       

摘要

Mip (macrophage infectivity potentiator) and Mip-like proteins are virulence factors in a wide range of pathogens including Legionella pneumophila. These proteins belong to the FK506 binding protein (FKBP) family of peptidyl-prolyl-cis/trans-isomerases (PPIases). In L. pneumophila the PPIase activity of Mip is required for invasion of macrophages, transmigration through an in vitro lung-epithelial barrier, and full virulence in the guinea pig infection model. Additionally, Mip is a moonlighting protein that binds to collagen IV in the extracellular matrix. Here, we describe the development, and synthesis of cycloheximide derivatives with adamantyl moieties as novel FKBP ligands, and analyze their effect on the viability of L. pneumophila and other bacteria. All compounds efficiently inhibited PPIase activity of the prototypic human FKBP12 as well as Mip with IC50-values as low as 180 nM and 1.7 μM, respectively. Five of these derivatives inhibited the growth of L. pneumophila at concentrations of 30 to 40 μM, but exhibited no effect on other tested bacterial species indicating a specific spectrum of antibacterial activity. The derivatives carrying a 3,5‐dimethyladamantan‐1‐[yl]acetamide substitution (MT_30.32), and a 3‐ethyladamantan‐1‐[yl]acetamide substitution (MT_30.51) had the strongest effects in PPIase- and liquid growth assays. MT_30.32 and MT_30.51 were also inhibitory in macrophage infection studies without being cytotoxic. Accordingly, by applying a combinatorial approach we were able to generate novel, hybrid inhibitors consisting of cycloheximide and adamantane, two known FKBP inhibitors that interact with different parts of the PPIase domain, respectively. Interestingly, despite the proven Mip-inhibitory activity, the viability of a Mip-deficient strain was affected to the same degree as its wild type. Hence, we also propose that cycloheximide derivatives with adamantyl moieties are potent PPIase inhibitors with multiple targets in L. pneumophila.
机译:Mip(巨噬细胞感染增强剂)和Mip样蛋白是包括肺炎军团菌在内的多种病原体的致病因子。这些蛋白属于肽基-脯氨酰-顺/反异构酶(PPIase)的FK506结合蛋白(FKBP)家族。在嗜肺乳杆菌中,Mip的PPIase活性对于巨噬细胞的侵袭,通过体外肺上皮屏障的迁移以及豚鼠感染模型中的完全毒力是必需的。此外,Mip是一种月光蛋白,可与细胞外基质中的IV型胶原结合。在这里,我们描述了开发和合成具有金刚烷基部分作为新的FKBP配体的环己酰亚胺衍生物,并分析了它们对嗜肺乳杆菌和其他细菌生存能力的影响。所有化合物均有效抑制原型人FKBP12和Mip的PPIase活性,IC50值分别低至180 nM和1.7μM。这些衍生物中的五种以30至40μM的浓度抑制了嗜肺乳杆菌的生长,但对其他受试细菌没有任何影响,表明其具有特定的抗菌活性谱。带有3,5-二甲基金刚烷-1- [基]乙酰胺取代(MT_30.32)和3-乙基金刚烷-1- [基]乙酰胺取代(MT_30.51)的衍生物在PPIase和液体中的作用最强生长测定。 MT_30.32和MT_30.51在巨噬细胞感染研究中也具有抑制作用,而没有细胞毒性。因此,通过应用组合方法,我们能够产生由环己酰亚胺和金刚烷组成的新型杂合抑制剂,这两种已知的FKBP抑制剂分别与PPIase域的不同部分相互作用。有趣的是,尽管已证明了Mip抑制活性,但Mip缺陷菌株的生存力受到了与野生型相同的影响。因此,我们还提出具有金刚烷基部分的环己酰亚胺衍生物是在嗜肺乳杆菌中具有多个靶标的有效PPIase抑制剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号